Pharming Group N.V. (PHAR) Misses Q3 EPS by 0c ; Offers Guidance

Pharming Group N.V. (NASDAQ: PHAR) reported Q3 EPS of $0.00, $0.00 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $74.8 million versus the consensus estimate of $76.93 million.

GUIDANCE:

Pharming Group N.V. sees FY2024 revenue of $280-295 million, versus the consensus of $284.5 million.

For earnings history and earnings-related data on Pharming Group N.V. (PHAR) click here.

You May Also Be Interested In

• Flutter Entertainment (FLUT) Reiterated at Market Outperform by Citizens
• Boeing (BA) call put ratio 3 calls to 1 put into share price lower before the bell
• Goldman Sachs: 'Our estimates for ANET, FFIV, and CLS 3Q26E are largely unchanged'